IRLAB Therapeutics AB
STO:IRLAB A

Watchlist Manager
IRLAB Therapeutics AB Logo
IRLAB Therapeutics AB
STO:IRLAB A
Watchlist
Price: 13.1 SEK 8.26% Market Closed
Market Cap: 678.4m SEK
Have any thoughts about
IRLAB Therapeutics AB?
Write Note

IRLAB Therapeutics AB
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

IRLAB Therapeutics AB
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
IRLAB Therapeutics AB
STO:IRLAB A
Accounts Payable
kr10.5m
CAGR 3-Years
42%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Calliditas Therapeutics AB
STO:CALTX
Accounts Payable
kr151m
CAGR 3-Years
37%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Accounts Payable
kr78.4m
CAGR 3-Years
35%
CAGR 5-Years
36%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Accounts Payable
kr116.7m
CAGR 3-Years
65%
CAGR 5-Years
93%
CAGR 10-Years
N/A
Moberg Pharma AB (publ)
STO:MOB
Accounts Payable
kr6.8m
CAGR 3-Years
32%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Accounts Payable
kr6.7m
CAGR 3-Years
-14%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
No Stocks Found

IRLAB Therapeutics AB
Glance View

Market Cap
679.5m SEK
Industry
Pharmaceuticals

IRLAB Therapeutics AB engages in the provision of novel treatments for disorders of the brain that focuses on illness in the central nervous system. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-02-28. The company focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The firm possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The firm operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

IRLAB A Intrinsic Value
16.06 SEK
Undervaluation 18%
Intrinsic Value
Price

See Also

What is IRLAB Therapeutics AB's Accounts Payable?
Accounts Payable
10.5m SEK

Based on the financial report for Dec 31, 2023, IRLAB Therapeutics AB's Accounts Payable amounts to 10.5m SEK.

What is IRLAB Therapeutics AB's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
12%

Over the last year, the Accounts Payable growth was 5%. The average annual Accounts Payable growth rates for IRLAB Therapeutics AB have been 42% over the past three years , 12% over the past five years .

Back to Top